MedTrace Logo

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

NCT05744401 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2026-02-25

Study results available
· View outcomes & findings →

Summary

A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.

Conditions

Interventions

DRUG

AL002

Administered via intravenous (IV) infusion

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Alector Inc.

    lead INDUSTRY

Principal Investigators

  • TBD TBD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-04
Primary Completion
2025-01-31
Completion
2025-02-05
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05744401 on ClinicalTrials.gov